2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T6d0,Real-world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited. To evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD. This prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient-Oriented Eczema Measure (POEM), Patient-Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib-treated patients. Adverse events were monitored during each visit. Thirty-eight patients were included, of which 32 patients had HE. At Week 16, EASI-75 was achieved by 50.0%. Absolute cutoff score NRS-pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT <7 by 68.8%, and PGAD rating of at least 'good' by 53.1%. HECSI-75 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub-analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials. Upadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non-atopic individuals.31:T870,AbstractBackgroundReal‐world data on the effectiveness of upadacitinib on atopic dermatitis (AD), hand eczema (HE) and HE in the context of AD are limited.ObjectivesTo evaluate the effectiveness and safety of upadacitinib on AD and on HE in patients with AD.MethodsThis prospective observational cohort study includes clinical outcomes: Eczema Area and Severity Index (EASI), Investigator's Global Assessment (IGA), Hand Eczema Severity Index (HECSI), Photographic guide; and PROMs: average pruritus and pain Numeric Rating Scale (NRS) score of the past week, Patient‐Oriented Eczema Measure (POEM), Patient‐Oriented Eczema, Dermatology Life Quality Index (DLQI), Atopic Dermatitis Control Tool (ADCT), Patient Global Assessment of Disease (PGAD), Quality Of Life Hand Eczema Questionnaire (QOLHEQ) at baseline, Week 4, and Week 16 of upadacitinib‐treated patients. Adverse events were monitored during each visit.ResultsThirty‐eight patients were included, of which 32 patients had HE. At Week 16, EASI‐75 was achieved by 50.0%. Absolute cutoff score NRS‐pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT <7 by 68.8%, and PGAD rating of at least ‘good’ by 53.1%. HECSI‐75 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub‐analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials.ConclusionsUpadacitinib can be an effective treatment for patients with AD and concomitant HE in daily practice. Future studies should focus on the effectiveness of upadacitinib on chronic HE, especially on the different etiological subtypes of HE, including HE in non‐atopic individuals.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Hand Eczema: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Hand Eczema (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Hand%20Eczema\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Hand Eczema\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Hand%20Eczema\"}]}}"}}]],["$","$L2f",null,{"title":"Hand Eczema: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Hand Eczema with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1111/cod.14276","pmid":"36621910","title":"Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry","journal_title":"Contact Dermatitis","journal_issn":"0105-1873","published_at":"2023-01-10T00:00:00.000Z","url":"https://doi.org/10.1111/cod.14276","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-02-03","doi":"10.1111/cod.14276","days":"30","issn":"0105-1873","rank":"5","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/cod.14276","title":"Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry.","journal":"Contact dermatitis","methods":"","results":"Thirty-eight patients were included, of which 32 patients had HE. At Week 16, EASI-75 was achieved by 50.0%. Absolute cutoff score NRS-pruritus ≤4 was reached by 62.5%, POEM ≤7 by 37.5%, DLQI ≤5 by 59.4%, ADCT <7 by 68.8%, and PGAD rating of at least 'good' by 53.1%. HECSI-75 was achieved by 59.3% and (almost) clear on the Photographic guide by 74.1%. The minimally important change in QOLHEQ was achieved by 57.9%. Sub-analysis in patients with concomitant irritant contact dermatitis showed no differences. Safety analysis showed no new findings compared to clinical trials.","abstract":"$30","keywords":["atopic dermatitis","hand eczema","quality of life","treatment","upadacitinib"],"pubmed_id":"36621910","conclusions":"","publication_date":"2023-01-10T00:00:00"},"crossref":{"DOI":"10.1111/cod.14276","URL":"https://doi.org/10.1111/cod.14276","ISSN":["0105-1873","1600-0536"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/cod.14276","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/full-xml/10.1111/cod.14276","content-type":"application/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/cod.14276","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"351-362","type":"journal-article","issue":"5","score":1,"title":["Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry"],"author":[{"given":"Esmé","family":"Kamphuis","sequence":"first","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}]},{"given":"Laura","family":"Loman","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}]},{"given":"Henry L.","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}]},{"given":"Geertruida L. E.","family":"Romeijn","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}]},{"given":"Klaziena","family":"Politiek","sequence":"additional","affiliation":[{"name":"Department of Dermatology Medical Center Leeuwarden Leeuwarden The Netherlands"}]},{"given":"Marie L. A.","family":"Schuttelaar","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Groningen, University of Groningen Groningen The Netherlands"}]}],"funder":[{"id":[{"id":"10.13039/100004319","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004319","name":"Pfizer","doi-asserted-by":"publisher"},{"id":[{"id":"10.13039/100004339","id-type":"DOI","asserted-by":"publisher"}],"DOI":"10.13039/100004339","name":"Sanofi","doi-asserted-by":"publisher"}],"issued":{"date-parts":[[2023,1,19]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":"88","archive":["Portico"],"created":{"date-time":"2023-01-09T15:49:50Z","timestamp":1673279390000,"date-parts":[[2023,1,9]]},"indexed":{"date-time":"2025-08-24T01:35:58Z","timestamp":1755999358116,"date-parts":[[2025,8,24]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000,"date-parts":[[2023,1,19]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/cod.14276"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2022-09-23"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":1,"value":"2023-01-05"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":2,"value":"2023-01-19"}],"deposited":{"date-time":"2023-08-21T23:37:36Z","timestamp":1692661056000,"date-parts":[[2023,8,21]]},"issn-type":[{"type":"print","value":"0105-1873"},{"type":"electronic","value":"1600-0536"}],"published":{"date-parts":[[2023,1,19]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/all.13401","key":"e_1_2_10_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.13804","key":"e_1_2_10_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/actadv.v101.432","key":"e_1_2_10_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2310/6620.2006.06005","key":"e_1_2_10_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.16147","key":"e_1_2_10_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.13308","key":"e_1_2_10_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.14035","key":"e_1_2_10_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2009.09099.x","key":"e_1_2_10_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.14104","key":"e_1_2_10_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.18176/jiaci.0831","key":"e_1_2_10_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18311","key":"e_1_2_10_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18139","key":"e_1_2_10_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/DER.0000000000000809","key":"e_1_2_10_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.17705","key":"e_1_2_10_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2022.05.021","key":"e_1_2_10_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15575","key":"e_1_2_10_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.18137","key":"e_1_2_10_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.15346","key":"e_1_2_10_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jdcr.2020.10.023","key":"e_1_2_10_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/dth.14890","key":"e_1_2_10_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s40268-022-00396-1","key":"e_1_2_10_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/DER.0000000000000780","key":"e_1_2_10_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/1346-8138.16549","key":"e_1_2_10_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Domeingroep Allergie en eczeem domeingroep Kinderdermatologie VMCE. Upadacitinib (standpunt). Available from: Standpunten en leidraden (nvdv.nl). Assessed July 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1034/j.1600-0625.2001.100102.x","key":"e_1_2_10_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-3751","key":"e_1_2_10_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-1246","key":"e_1_2_10_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00403-021-02185-3","key":"e_1_2_10_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/archderm.140.12.1513","key":"e_1_2_10_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2230.1994.tb01167.x","key":"e_1_2_10_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/03007995.2019.1699516","key":"e_1_2_10_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-021-00558-0","key":"e_1_2_10_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2004.06305.x","key":"e_1_2_10_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/j.1365-2133.2004.06270.x","key":"e_1_2_10_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18558","key":"e_1_2_10_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jid.2019.08.450","key":"e_1_2_10_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bundesanstalt für Arbeitsschutz und Arbeitsmedizin.TRGS 401: Risks Resulting from Skin Contact—Identification Assessment Measures[Internet].2008. Assessed July 2022.https://www.baua.de/DE/Angebote/Rechtstexte-und-Technische-Regeln/Regelwerk/TRGS/TRGS-401.html","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1016/j.shaw.2014.08.001","key":"e_1_2_10_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention. Available from: Global Initiative for Asthma (GINA) (ginasthma.org). Assessed July 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/j.1398-9995.2007.01620.x","key":"e_1_2_10_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ad.2019.05.009","key":"e_1_2_10_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jclinepi.2006.01.014","key":"e_1_2_10_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s11121-007-0070-9","key":"e_1_2_10_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"SimpsonEL RahawiK HuX.Effect of Upadacitinib on Hand Eczema in Patients With Moderate‐to‐Severe Atopic Dermatitis: Results from Two Phase 3 Trials (Measure Up 1 and Measure Up 2). Presented at the 30th European Academy of Dermatology and Venereology Congress September 29–October 2 2021 EADV Virtual Congress (e‐poster unpublished).","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1007/s40257-018-0413-2","key":"e_1_2_10_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/13543784.2022.2087059","key":"e_1_2_10_47_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18469","key":"e_1_2_10_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.21037","key":"e_1_2_10_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Business Wire.Asana biosciences announces positive topline results from phase 2b study of oral JAK‐SYK inhibitor gusacitinib (ASN002) in patients with chronic hand eczema: rapid and significant improvement demonstrated [press release]. Available from: Asana BioSciences Announces Positive Topline Results from Phase 2b Study of Oral JAK/SYK Inhibitor Gusacitinib (ASN002) in Patients with Chronic Hand Eczema: Rapid and Significant Improvement Demonstrated | Business Wire. Assessed July 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1186/s12895-019-0095-3","key":"e_1_2_10_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2021.4778","key":"e_1_2_10_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1186/s13075-016-1151-6","key":"e_1_2_10_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31191-1","key":"e_1_2_10_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_10_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Smoking Pack Years. Available from: Home | Smoking Pack Years. Assessed July 2022.","article-title":null,"journal-title":null,"doi-asserted-by":null},{"DOI":"10.1111/cod.12912","key":"e_1_2_10_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/cod.12993","key":"e_1_2_10_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/cod.14276"],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Contact Dermatitis"],"published-print":{"date-parts":[[2023,5]]},"reference-count":56,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2023,1,19]]},"references-count":56,"short-container-title":["Contact Dermatitis"],"is-referenced-by-count":17},"unpaywall":{"doi":"10.1111/cod.14276","is_oa":true,"title":"Experiences from daily practice of upadacitinib treatment on atopic dermatitis with a focus on hand eczema: Results from the BioDay registry","updated":"2025-09-14T03:39:29+00:00","published_date":"2023-01-09","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cod.14276","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cod.14276","url_for_landing_page":"https://doi.org/10.1111/cod.14276"}}},"created_at":"2025-09-22T14:20:55.574Z","updated_at":"2025-09-22T14:20:55.574Z","tags":[{"paper_doi":"10.1111/cod.14276","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"condition","value":"Hand Eczema","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"sample_size","value":"n=38","value_numeric":38},{"paper_doi":"10.1111/cod.14276","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"warning","value":"Observational design without a comparator limits causal inference.","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"warning","value":"Population details (age, sex) are not provided in the abstract.","value_numeric":null},{"paper_doi":"10.1111/cod.14276","tag_type":"warning","value":"Primary outcome not specified; multiple endpoints reported.","value_numeric":null}],"summaries":{"what_studied":"A prospective observational cohort of 38 upadacitinib‑treated patients with atopic dermatitis (32 with hand eczema) assessed outcomes at baseline, Week 4, and Week 16, with adverse events recorded.","key_result":"At Week 16, EASI‑75 was achieved by 50.0%; patient‑reported milestones included NRS‑pruritus ≤4 in 62.5%, POEM ≤7 in 37.5%, DLQI ≤5 in 59.4%, ADCT <7 in 68.8%, and PGAD at least 'good' in 53.1%. For hands, HECSI‑75 was reached by 59.3%, (almost) clear on the Photographic guide by 74.1%, and the minimally important change in QOLHEQ by 57.9%; safety showed no new findings versus clinical trials.","limitations":"Small sample (n=38), no control group, and follow‑up limited to 16 weeks. Results are in AD patients; non‑atopic chronic hand eczema was not studied.","practice_takeaway":"In routine practice, upadacitinib improved AD signs/symptoms and concomitant hand eczema by 16 weeks with no new safety signals. Use these data as supportive real‑world evidence, recognizing the short‑term, uncontrolled design."}}],"initialOffset":1,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Hand Eczema"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Hand Eczema"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Hand Eczema"}}}]]

Papers